Mount Sinai Hospital (Manhattan)

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

Retrieved on: 
Wednesday, January 17, 2024
Medical Devices, Surgery, FDA, Clinical Trials, Cardiology, Practice Management, Other Health, Biotechnology, Radiology, Health, Diabetes, Patient, Amputation, Kidney, Calf, Knee, Finesse, Angiography, Multimedia, DRS, Risk, Chronic kidney disease, Mount Sinai Hospital (Manhattan), PAD, Medical imaging

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to facilitate treatment of patients at risk of limb loss due to below-knee PAD.
  • It was designed to improve the efficiency of peripheral angioplasty procedures by reducing equipment and contrast needs.
  • “In our busy limb salvage practice, it will be an important tool.”
    The Summa Finesse Injectable is a multifunctional catheter that serves as a crossing catheter, diagnostic angiography catheter, and angioplasty catheter to reduce equipment and contrast needs.
  • The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa.

Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry

Retrieved on: 
Thursday, November 16, 2023
TAVR, Safety, NYSE, TFX, Cardiology, Structural heart disease, Patient, Registry, Interventional cardiology, Intervention, Hemostasis, SAFE, Teleflex, Doctor of Philosophy, Mount Sinai Medical Center, VCD, Mount Sinai Hospital (Manhattan), Medical device, Medical imaging, Hospital, Surgery, MD

The registry will include appropriate patient selection and proper vascular access.

Key Points: 
  • The registry will include appropriate patient selection and proper vascular access.
  • Enrolling at least 250 patients in up to 15 major TAVR institutions across the US and Canada, the ACCESS-MANTA™ Registry is an international, multicenter, prospective, observational, single-arm clinical registry.
  • “Large bore access site complications are recognized as morbid,1 driving increased costs and prolonged length-of-stay,2” said Teleflex Interventional Medical Director, Christopher Buller, MD.
  • “We are excited that Mount Sinai Medical Center is spearheading the Teleflex ACCESS-MANTA™ Registry,” said Dr. Khera, Co-Global Principal Investigator.

iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Research, Safety, Nerve, CTN, Gene editing, Ornithine transcarbamylase deficiency, Pediatrics, Gene, University, Coma, Mouse, Liver, Clinical trial, Disease, Risk, TGA, Patient, GTP, Nervous system, Pharmacokinetics, Child, Blood, Primate, Trial of the century, Ammonia, Death, Metabolic disorder, Neurology, Quality of life, OTC, Mount Sinai Hospital (Manhattan), Pharmaceutical industry, Dietary supplement, Medicine

“The TGA’s clearance to begin clinical trials for the OTC-HOPE study represents major milestones for the OTC deficiency community and for the iECURE team,” said Joe Truitt, Chief Executive Officer of iECURE.

Key Points: 
  • “The TGA’s clearance to begin clinical trials for the OTC-HOPE study represents major milestones for the OTC deficiency community and for the iECURE team,” said Joe Truitt, Chief Executive Officer of iECURE.
  • “ECUR-506 has the potential to restore the function of the OTC enzyme in infants who lack this critical component of the urea cycle.
  • We are hopeful that our approach will be a better option for these children.”
    The OTC-HOPE study is a Phase 1/2 first-in-human study in baby boys with genetically confirmed neonatal-onset OTC deficiency.
  • Currently available medical therapies do not correct the disease and do not eliminate the risk of life-threatening symptoms or crises.

Mount Sinai Phillips School of Nursing Appoints New Dean

Retrieved on: 
Tuesday, November 14, 2023
Theta, Senior, DNP, American Nurses Association, BSN, George Fox University, Map, Gay Nurses Alliance, Traditional Chinese medicine, NYU, Growth, Doctor of Philosophy, Administration, School, Physician, American Academy, NYU Langone Health, Health, Mount Sinai Hospital (Manhattan), Jewish-American organized crime, Dean (education), FAAN, Student, Distinguishing, Mount Sinai Health System, University, Medicare, College, RN, Faculty, American Academy of Nursing, PSON, Mount Sinai Hospital, Nursing, New York University

NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN, has been appointed as the new Dean of the Mount Sinai Phillips School of Nursing (PSON) and Vice President for Nursing Academic Affairs of the Mount Sinai Health System, effective Friday, December 29.

Key Points: 
  • Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN, has been appointed as the new Dean of the Mount Sinai Phillips School of Nursing.
  • NEW YORK, Nov. 14, 2023 /PRNewswire-PRWeb/ -- Kimberly Glassman, PhD, RN, NEA-BC, FAONL, FAAN, has been appointed as the new Dean of the Mount Sinai Phillips School of Nursing (PSON) and Vice President for Nursing Academic Affairs of the Mount Sinai Health System, effective Friday, December 29.
  • The unique, integrated relationship between PSON and the Mount Sinai Health System supports our nursing students with combined classroom and clinical experiences."
  • "The unique, integrated relationship between PSON and the Mount Sinai Health System supports our nursing students with combined classroom and clinical experiences, providing a rich foundation for their entry into clinical practice and their nursing career."

Results from Magenta Medical's US Early Feasibility Study of the World's Smallest and Most Powerful Heart Pump to be Highlighted at TCT 2023

Retrieved on: 
Tuesday, October 10, 2023
Coronary artery disease, Mount Sinai Hospital (Manhattan), Percutaneous coronary intervention, Safety, Hospital, Teaching hospital, Diagnosis, Cardiology, Mount Sinai Hospital, Magenta, Ventricular assist device, Interventional cardiology, Philippine Heart Center, North Shore University Hospital, St. Francis Hospital, TCT, Patient, Pharmaceutical industry, Medical device

KADIMA, Israel , Oct. 10, 2023 /PRNewswire/ --Results from Magenta Medical's Early Feasibility Study of the Elevate™ System, for the high-risk percutaneous coronary intervention (HR-PCI) indication, will be announced in an oral presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco. Elevate™ is the world's smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).

Key Points: 
  • Elevate™ is the world's smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).
  • Presentation title: Magenta Elevate™: First US Experience with High-Output, Low-French Size Percutaneous Mechanical Circulatory Support
    Session: TCT Innovation V: Innovation in Coronary Disease Diagnosis and Therapies/Featured Technological Trends: Percutaneous Mechanical Circulatory Support.
  • Magenta's US Early Feasibility Study was initiated to evaluate the safety and feasibility of the Elevate™ System in providing temporary mechanical circulatory support during HR-PCI procedures.
  • Fifteen patients were treated in the study at the Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital.

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Retrieved on: 
Thursday, September 21, 2023
Leona, HSCS, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital (Manhattan), Cardiovascular disease, ECG, Intelligence, Research, Doctor of Philosophy, Assistant, Annals of Pediatric Cardiology, Cardiac electrophysiology, Science, Patent, Patient, Division, Mount Sinai Hospital, Algorithm, Machine learning, Cardiology, Diagnosis, Policy, MPH, Mount Sinai Health System, Death, D3M, Medical device, Management, Pharmaceutical industry, MD, Medicine

HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.

Key Points: 
  • HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.
  • HeartSciences and Icahn Mount Sinai have also entered into a memorandum of understanding for ongoing cooperation encompassing de-identified data access, on-going research, and the evaluation of HeartSciences’ MyoVista® wavECGTM.
  • Mount Sinai and Mount Sinai faculty, including Dr. Nadkarni; Dr. Vaid; Joshua Lampert, MD, Medical Director of Machine Learning for Mount Sinai Heart; Vivek Reddy, MD, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn Mount Sinai; and Son Duong, MD, Assistant Professor of Pediatrics (Pediatric Cardiology) at Icahn Mount Sinai, have a financial interest in this technology and in HeartSciences.
  • The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.

The Mount Sinai Hospital Commemorates 75th Anniversary of First Dialysis Procedure with Continuing Medical Education Event

Retrieved on: 
Thursday, September 21, 2023
CME, Kidney disease, Maintenance, Mount Sinai Hospital, Diabetes, Q&A, Icahn School of Medicine at Mount Sinai, Nephrology, Physician, Mount Sinai Hospital (Manhattan), Internal medicine, Hope, History, Doctor of Philosophy, Associate, Dialysis, CDC, Pain, Student, Chronic kidney disease, MD, Patient, Urology, Nursing, Blood, Korea Disease Control and Prevention Agency, AMA, Ethics, European Review for Medical and Pharmacological Sciences, Salt, Health, Death, Health information management, Medical device, Pharmaceutical industry

NEW YORK, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Seventy-five years after pioneering doctors at The Mount Sinai Hospital conducted the first hemodialysis treatment in the United States, the hospital is marking progress to date in a continuing medical education (CME) event on Monday, October 2. The event will be led by innovators in the field of nephrology who are exploring advancements and innovations for a growing population of adults requiring dialysis. Additional details about the course, still open for registration, can be found online.

Key Points: 
  • NEW YORK, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Seventy-five years after pioneering doctors at The Mount Sinai Hospital conducted the first hemodialysis treatment in the United States, the hospital is marking progress to date in a continuing medical education (CME) event on Monday, October 2.
  • The event will be led by innovators in the field of nephrology who are exploring advancements and innovations for a growing population of adults requiring dialysis.
  • There will also be a dialysis history exhibit in Mount Sinai's Guggenheim Pavilion, which will be open to attendees prior to the symposium.
  • Course director and moderator Jaime Uribarri, MD, Professor of Medicine (Nephrology) at the Icahn School of Medicine at Mount Sinai, directs The Mount Sinai Hospital's Home Dialysis Program, one of the largest in New York City.

Fat Burning During Exercise Varies Widely Between Individuals; Study reveals limitations of commercial exercise machines

Retrieved on: 
Friday, August 11, 2023
Exercise, CDN, Obesity, University, Metabolism, Intelligence, Mount Sinai Hospital (Manhattan), Department of Medicine – University of Pamplona, Cardiovascular disease, Mount Sinai, Doctor of Philosophy, Division, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Tel Aviv Sourasky Medical Center, Heart rate, Weight, MPH, Medical imaging, Dietary supplement, Nutrition, RD, MD, Mount Sinai Morningside, Medicine

NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.

Key Points: 
  • The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • "People with a goal of weight or fat loss may be interested in exercising at the intensity which allows for the maximal rate of fat burning.
  • "We hope that this work will inspire more individuals and trainers to utilize clinical exercise testing to prescribe personalized exercise routines tailored to fat loss.

Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System

Retrieved on: 
Wednesday, May 31, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, McGill University Health Centre, Heart, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inc., EU, Vein, Atrial fibrillation, Mount Sinai Hospital (Manhattan), PFA, Sale, Trial of the century, Electrode, Gold, Mount Sinai Hospital, MD, Patient, Mount, AF, IDE, FDA, Food, Safety, Medical device

The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.

Key Points: 
  • The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
  • The study expands on the successful Globe System PULSE-EU study of 69 patients treated in Prague, Czech Republic.
  • “As a next generation pulsed field system, the Globe System allows precise delivery of pulsed field energy.
  • Kardium Inc. (kardium.com) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe® System.

Two Renowned Cancer Experts to Head New Tisch Cancer Hospital at The Mount Sinai Hospital

Retrieved on: 
Thursday, March 16, 2023
National Cancer Institute (Egypt), Research, Cancer, Health, Nephrology, Nursing, MD, Hospital, Trustee, Bangladesh Technical Education Board, Department of Defense Serum Repository, Medicine, Mount Sinai Hospital (Manhattan), School, Mount Sinai Health System, Principal investigator, Surgeon, Prostate cancer, Informatics, Icahn School of Medicine at Mount Sinai, Social justice, Patient, Sinai Health System, Interference microscopy, Madison Avenue, National Cancer Institute, Medical director, American Cancer Society, Master of Surgery, Faculty, MBBS, Surgical oncology, Cardiology, Knowledge, Health system, Doctor of Philosophy, Geriatrics, Lead, News, Artificial intelligence, Dentistry, Tisch, Urology

NEW YORK, March 16, 2023 /PRNewswire-PRWeb/ -- Two top cancer experts have been named to lead Mount Sinai's new Tisch Cancer Hospital, which is under development and due to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.

Key Points: 
  • Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer for the Tisch Cancer Hospital and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief of the Tisch Cancer Hospital.
  • The Tisch Cancer Hospital will be a state-of-the-art cancer facility at The Mount Sinai Hospital, thanks to a generous $60 million gift from James S. and Merryl H. Tisch.
  • "Mount Sinai's vision for the Tisch Cancer Hospital was bold," said Mr. Tisch, Co-Chairman of the Boards of Trustees of the Mount Sinai Health System.
  • "The Tisch Cancer Hospital will be a hospital within the hospital that is supported by experts from various areas of medicine," Dr. Tewari said.